


Designing in sustainability

2021 Performance highlights



Who we are

Our vision is a world in which access to life-changing therapies transforms human health.

Our mission is to advance and accelerate therapeutics.

Cytiva, part of Danaher, is a global life sciences leader working with customers who are developing life-changing therapeutics. From monoclonal antibodies, to new cell and gene therapies and mRNA vaccines, our technologies and solutions enable the safe, effective, and fast development of novel therapeutics.

Some of our brands

ÄKTA™

HyClone™

Whatman™

Amersham™

KUBio™

Xcellerex™


Biacore™

MabSelect™

Xuri™

FlexFactory™

Sera-Mag™



9500+

Associates dedicated to our mission.

40+

Countries and territories of operation.

11

Customer-centered innovation facilities.

Our outcomes

- Recognized expert in antibody purification.
- Majority of mAbs approved by the FDA in 2020 use Cytiva technologies in manufacture.
- 5198 patents and patent applications filed.




Our focus on people, planet, and foundation works across the entire industry or not at all. By collaborating strategically, we've reached a different level of relationship with customers. We are exploring how we can do more together to tackle the environmental and social impacts we share.

Emmanuel Ligner
President and CEO



Designing in sustainability

Designing in sustainability captures three opportunities for change — for people, for our planet, and for our foundation. Our plan is designed to deliver positive impact and helps us rethink the way we do business.



People

To help people thrive, we're making a positive impact on health, society, and local communities while increasing diversity in our sector.

400+

COVID-19 vaccine studies began in 2020; the majority were supported by Cytiva.

\$2M

Cytiva's USD investments in 2021 to support social impact programs and diversity initiatives.


37%

of our global workforce are women.



We constantly need new talent, and there's nothing more rewarding than to meet someone that just joined and to learn that they chose Cytiva because of our sustainability program.

Emmanuel Ligner
President and CEO



On target for women and people of color

With 37% of our global workforce comprised of women, we are on track to achieve our 2025 target of 40%. Even with a significant increase in overall headcount over the last two years, female representation remains stable. The scope of female managers and executives has been restated for 2020 and 2021 to reflect organizational changes.

Also on track for our 2025 target of 38%, people of color in the US rose from 26% in 2020 to 28% in 2021.



Growing diverse talent

Cytiva is collaborating with Biomedical Science Careers Program to increase the number of underrepresented minorities and disadvantaged individuals in healthcare.

\$320K

investment in future scientists.



Feeling engaged

The engagement scores from our 2021 associate survey were encouraging. We received an 87% response rate.

80%

confirm that they feel engaged at Cytiva.

85%

believe Cytiva is an inclusive organization.



Investing in innovation

In Sweden, South Korea, China, Australia and New Zealand, we've been holding open competitions and providing grants and resources to promising biotech start-ups.

\$142K

in VivaZome's exosome-derived therapies.

\$300K

in China's 'Think Biomedical Innovation Project'.

Planet

To help our planet thrive, we're tackling climate change and making smarter use of resources.

40%

of our manufacturing sites are now powered by renewable electricity.

5%

absolute reduction in CO₂e emissions from operations since 2019.


12K

products reweighed and remeasured to reduce packaging void fill.



Water is a big challenge — one approach we have is to take one of our plants in an area where there is no water challenge today and see what are the measures we can take now to actively reduce our consumption of water so we are ready for potential shortages.

Emmanuel Ligner
President and CEO



Decoupling growth from CO₂ emissions

Since our 2019 baseline year, our business has grown and at the same time, we have reduced absolute CO₂ emissions from our operations by 5% (Scope 1 and 2 emissions). Water use only increased 3% in the same growth period.



Reducing shipping CO₂

By applying smart logistics — as in rethinking packaging, shifting transport modes, and applying more direct routes — we reduced carbon emissions and saved money.

1300

tCO₂ saved.

\$3.4M

in logistics costs saved.

Saving local water

We conducted a kaizen using the DBS toolkit called 4E — environmental, ergonomics, exposures, and energetics — in Logan, US, one of our most water-intensive sites where we identified opportunities to reduce water use by 51%.

87M

liters (23 gallons) water savings potential in just one building.

Streaming remote FAT

Due to restricted in-person meetings due to COVID-19, we introduced live-stream remote factory acceptance tests (FATs).

253

remote FATs conducted.

24

tCO₂ reduced per test.

Foundation

The processes, priorities, and relationships we build to shape a resilient company.

70%

of our purchasing spend has been assessed on supplier sustainability performance.

22%

reduction in health and safety incident rate since 2017.


100%

manufacturing sites encompassed in our ISO 14001 certification.




The pandemic forced us to think about our supply chain strategy – where are we going to put our plants, how can we provide access to new customers at a different volume than in the past? So, the way we are looking at deploying that 1.5B USD of investment that we announced last year, is through the eyes of sustainability.

Emmanuel Ligner
President and CEO



Cytiva supplier rankings and the EcoVadis industry benchmark

At year-end, 319 Cytiva suppliers were assessed according to EcoVadis supplier scorecard. With an overall score of 52, their rating exceeds the EcoVadis industry benchmark of 43.8. The majority of assessed suppliers were considered 'Engaged' or 'Opportunity' on Ecovadis' performance scale.




Thinking circular

We've recently revised our new product introduction process to include principles to reduce, reuse, and recycle that go beyond regulatory compliance. This framework was piloted on six new products in 2021 and used in four lifecycle assessments.

100%

adoption in all new products.



Driving innovation

In 2021 we invested \$3.8M to implement six winning ideas from our Planet Business Innovation Accelerator, a company-wide call for ideas that address sustainability and sharpen our business model.

\$3.8M

invested in six projects.



Reducing CO₂ impact

Thinking sustainably means making the right investments. By applying a financial indicator to our climate impacts, we can prioritize sustainability in our capital expenses.

\$550M

earmarked for sustainable capital expenditures.



Our commitment to sustainability

Thriving people, thriving planet, a resilient business. For Cytiva, these three aims are deeply connected. Achieving them is our ambition and our responsibility. That's why we commit to integrating respect for people and care of the environment in our decisions in ways that have a lasting impact on society, our customers, patients, and Cytiva associates.



Want to learn more?
cytiva.com/sustainability

[cytiva.com/sustainability](https://www.cytiva.com/sustainability)

Cytiva and the Drop logo are trademarks of of Life Sciences IP Holdings Corp. or an affiliate doing business as Cytiva.

ÄKTA, Amersham, Biacore, FlexFactory, HyClone, KUBio, MabSelect, Sera-Mag, Whatman, Xcellerex, and Xuri are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

© 2022 Cytiva

For local office contact information, visit [cytiva.com/contact](https://www.cytiva.com/contact)

CY30026-14Jun22-BR

